Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2024 | Jul. 26, 2024 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001549084 | |
Entity Registrant Name | EKSO BIONICS HOLDINGS, INC. | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2024 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2024 | |
Document Transition Report | false | |
Entity File Number | 001-37854 | |
Entity Incorporation, State or Country Code | NV | |
Entity Tax Identification Number | 99-0367049 | |
Entity Address, Address Line One | 101 Glacier Point, Suite A | |
Entity Address, City or Town | San Rafael | |
Entity Address, State or Province | CA | |
Entity Address, Postal Zip Code | 94901 | |
City Area Code | 510 | |
Local Phone Number | 984-1761 | |
Title of 12(b) Security | Common Stock, $0.001 par value per share | |
Trading Symbol | EKSO | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | true | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 18,444,181 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Current assets: | ||
Cash and restricted cash | $ 5,885 | $ 8,638 |
Accounts receivable, net of allowances of $28 and $79, respectively | 6,520 | 5,645 |
Inventories | 4,974 | 5,050 |
Prepaid expenses and other current assets | 1,263 | 875 |
Total current assets | 18,642 | 20,208 |
Property and equipment, net | 1,748 | 2,018 |
Right-of-use assets | 989 | 977 |
Intangible assets, net | 4,739 | 4,892 |
Goodwill | 431 | 431 |
Other assets | 435 | 392 |
Total assets | 26,984 | 28,918 |
Current liabilities: | ||
Accounts payable | 2,125 | 1,847 |
Accrued liabilities | 1,973 | 2,664 |
Deferred revenues, current | 1,926 | 1,993 |
Note payable, current | 1,250 | 1,250 |
Lease liabilities, current | 430 | 363 |
Total current liabilities | 7,704 | 8,117 |
Deferred revenues | 2,016 | 2,169 |
Notes payable, net | 4,352 | 4,832 |
Lease liabilities | 659 | 723 |
Warrant liabilities | 49 | 366 |
Other non-current liabilities | 145 | 105 |
Total liabilities | 14,925 | 16,312 |
Commitments and contingencies (Note 14) | ||
Stockholders’ equity: | ||
Convertible preferred stock, $0.001 par value; 10,000 shares authorized; none issued and outstanding at June 30, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 141,429 shares authorized; 18,444 and 14,848 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | 19 | 15 |
Additional paid-in capital | 256,491 | 251,580 |
Accumulated other comprehensive income | 539 | 156 |
Accumulated deficit | (244,990) | (239,145) |
Total stockholders’ equity | 12,059 | 12,606 |
Total liabilities and stockholders’ equity | $ 26,984 | $ 28,918 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($) shares in Thousands, $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Allowance for doubtful accounts | $ 28 | $ 79 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 10,000 | 10,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 141,429 | 141,429 |
Common stock, issued (in shares) | 18,444 | 14,848 |
Common stock, outstanding (in shares) | 18,444 | 14,848 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenue | $ 4,950 | $ 4,703 | $ 8,706 | $ 8,825 |
Cost of revenue | 2,313 | 2,449 | 4,118 | 4,571 |
Gross profit | 2,637 | 2,254 | 4,588 | 4,254 |
Operating expenses: | ||||
Sales and marketing | 1,846 | 2,349 | 3,664 | 4,437 |
Research and development | 1,116 | 1,398 | 2,252 | 2,552 |
General and administrative | 2,010 | 2,791 | 4,263 | 5,997 |
Total operating expenses | 4,972 | 6,538 | 10,179 | 12,986 |
Loss from operations | (2,335) | (4,284) | (5,591) | (8,732) |
Other (expense) income, net: | ||||
Interest expense, net | (74) | (61) | (131) | (172) |
Loss on modification of warrant | 0 | 0 | (109) | 0 |
Gain on revaluation of warrant liabilities | 84 | 152 | 426 | 126 |
Unrealized (loss) gain on foreign exchange | (91) | (7) | (440) | 210 |
Other expense, net | 0 | (30) | 0 | (51) |
Total other (expense) income, net | (81) | 54 | (254) | 113 |
Net loss | (2,416) | (4,230) | (5,845) | (8,619) |
Other comprehensive income (loss) | 92 | (10) | 383 | (204) |
Comprehensive loss | $ (2,324) | $ (4,240) | $ (5,462) | $ (8,823) |
Net loss per share applicable to common shareholders, basic and diluted (in dollars per share) | $ (0.13) | $ (0.31) | $ (0.33) | $ (0.64) |
Weighted average number of common shares outstanding, basic and diluted (in shares) | 18,224 | 13,637 | 17,822 | 13,467 |
Condensed Consolidated Statem_2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | AOCI Attributable to Parent [Member] | Retained Earnings [Member] | Total |
Balance (in shares) at Dec. 31, 2022 | 0 | 13,203 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 13 | $ 248,813 | $ 563 | $ (223,947) | $ 25,442 |
Net loss | $ 0 | $ 0 | 0 | 0 | (4,389) | (4,389) |
Equity incentive plan (in shares) | 0 | 139 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 424 | 0 | 0 | 424 |
Foreign currency translation adjustments | $ 0 | $ 0 | 0 | (194) | 0 | (194) |
Balance (in shares) at Mar. 31, 2023 | 0 | 13,342 | ||||
Balance at Mar. 31, 2023 | $ 0 | $ 13 | 249,237 | 369 | (228,336) | 21,283 |
Balance (in shares) at Dec. 31, 2022 | 0 | 13,203 | ||||
Balance at Dec. 31, 2022 | $ 0 | $ 13 | $ 248,813 | 563 | (223,947) | 25,442 |
Net loss | (8,619) | |||||
Matching contribution to 401(k) plan (in shares) | 161 | |||||
Matching contribution to 401(k) plan | $ 249 | |||||
Balance (in shares) at Jun. 30, 2023 | 0 | 13,807 | ||||
Balance at Jun. 30, 2023 | $ 0 | $ 14 | 250,000 | 359 | (232,566) | 17,807 |
Balance (in shares) at Mar. 31, 2023 | 0 | 13,342 | ||||
Balance at Mar. 31, 2023 | $ 0 | $ 13 | 249,237 | 369 | (228,336) | 21,283 |
Net loss | $ 0 | $ 0 | 0 | 0 | (4,230) | (4,230) |
Matching contribution to 401(k) plan (in shares) | 0 | 161 | ||||
Matching contribution to 401(k) plan | $ 0 | $ 0 | 249 | 0 | 0 | 249 |
Equity incentive plan (in shares) | 0 | 304 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 514 | 0 | 0 | 514 |
Foreign currency translation adjustments | $ 0 | 0 | 0 | (10) | 0 | (10) |
Equity incentive plan | $ 1 | 1 | ||||
Balance (in shares) at Jun. 30, 2023 | 0 | 13,807 | ||||
Balance at Jun. 30, 2023 | $ 0 | $ 14 | 250,000 | 359 | (232,566) | 17,807 |
Balance (in shares) at Dec. 31, 2023 | 0 | 14,848 | ||||
Balance at Dec. 31, 2023 | $ 0 | $ 15 | 251,580 | 156 | (239,145) | 12,606 |
Net loss | $ 0 | $ 0 | 0 | 0 | (3,429) | (3,429) |
Equity financing, net (in shares) | 0 | 2,997 | ||||
Equity financing, net | $ 0 | $ 3 | 3,967 | 0 | 0 | 3,970 |
Matching contribution to 401(k) plan (in shares) | 0 | 163 | ||||
Matching contribution to 401(k) plan | $ 0 | $ 0 | 237 | 0 | 0 | 237 |
Equity incentive plan (in shares) | 0 | 88 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 376 | 0 | 0 | 376 |
Foreign currency translation adjustments | $ 0 | $ 0 | 0 | 291 | 0 | 291 |
Balance (in shares) at Mar. 31, 2024 | 0 | 18,096 | ||||
Balance at Mar. 31, 2024 | $ 0 | $ 18 | 256,160 | 447 | (242,574) | 14,051 |
Balance (in shares) at Dec. 31, 2023 | 0 | 14,848 | ||||
Balance at Dec. 31, 2023 | $ 0 | $ 15 | $ 251,580 | 156 | (239,145) | 12,606 |
Net loss | (5,845) | |||||
Matching contribution to 401(k) plan (in shares) | 163 | |||||
Matching contribution to 401(k) plan | $ 238 | |||||
Balance (in shares) at Jun. 30, 2024 | 0 | 18,444 | ||||
Balance at Jun. 30, 2024 | $ 0 | $ 19 | 256,491 | 539 | (244,990) | 12,059 |
Balance (in shares) at Mar. 31, 2024 | 0 | 18,096 | ||||
Balance at Mar. 31, 2024 | $ 0 | $ 18 | 256,160 | 447 | (242,574) | 14,051 |
Net loss | $ 0 | $ 0 | 0 | 0 | (2,416) | (2,416) |
Equity financing, net (in shares) | 0 | 75 | ||||
Equity financing, net | $ 0 | $ 0 | 47 | 0 | 0 | 47 |
Equity incentive plan (in shares) | 0 | 273 | ||||
Stock-based compensation expense | $ 0 | $ 0 | 284 | 0 | 0 | 284 |
Foreign currency translation adjustments | $ 0 | 0 | 0 | 92 | 0 | 92 |
Equity incentive plan | $ 1 | |||||
Balance (in shares) at Jun. 30, 2024 | 0 | 18,444 | ||||
Balance at Jun. 30, 2024 | $ 0 | $ 19 | $ 256,491 | $ 539 | $ (244,990) | $ 12,059 |
Condensed Consolidated Statem_3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Operating activities: | ||
Net loss | $ (5,845) | $ (8,619) |
Adjustments to reconcile net loss to net cash used in operating activities | ||
Depreciation and amortization | 803 | 842 |
Changes in provision for credit losses on accounts receivable | 39 | 16 |
Gain on revaluation of warrant liabilities | (426) | (126) |
Stock-based compensation expense | 660 | 938 |
Loss on modification of warrant | 109 | 0 |
Common stock contribution to 401(k) plan | 113 | 219 |
Unrealized loss (gain) on foreign currency transactions | 440 | (210) |
Changes in operating assets and liabilities: | ||
Accounts receivable | (1,029) | (518) |
Inventories | (9) | (283) |
Prepaid expenses and other assets, current and noncurrent | (387) | (62) |
Accounts payable | 281 | (13) |
Accrued, lease and other liabilities, current and noncurrent | (681) | (61) |
Deferred revenues | (204) | 760 |
Net cash used in operating activities | (6,136) | (7,117) |
Investing activities: | ||
Acquisition of property and equipment | (8) | (97) |
Net cash used in investing activities | (8) | (97) |
Financing activities: | ||
Principal payments under note payable | (625) | 0 |
Proceeds from issuance of common stock, net | 4,017 | 0 |
Net cash provided by financing activities | 3,392 | 0 |
Effect of exchange rate changes on cash | (1) | (4) |
Net decrease in cash | (2,753) | (7,218) |
Cash and restricted cash at beginning of period | 8,638 | 20,525 |
Cash and restricted cash at end of period | 5,885 | 13,307 |
Supplemental disclosure of cash flow activities | ||
Cash paid for interest | 96 | 98 |
Cash paid for income taxes | 8 | 32 |
Supplemental disclosure of non-cash activities | ||
Transfer of inventory to (from) property and equipment | 72 | (131) |
Initial recognition of operating lease liability and right of use asset | 180 | 0 |
Share issuance RSU | 1 | 0 |
Share issuance for common stock contribution to 401(k) plan | $ 238 | $ 249 |
Note 1 - Organization
Note 1 - Organization | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Business Description and Basis of Presentation [Text Block] | 1. Organization Description of Business Ekso Bionics Holdings, Inc. (the “Company”) designs, develops, and markets wearable powered and non-powered exoskeleton products to augment human strength, endurance and mobility. The Company’s exoskeleton technology is primarily focused on aiding in the recovery and improved quality of life of individuals who have suffered from a variety of neurological conditions and allows for neurorehabilitation ranging from hospital to home, and also has technology that can be utilized by able-bodied users in the workplace. The Company has marketed devices that (i) enable individuals with neurological conditions affecting gait, including acquired brain injury ("ABI") and multiple sclerosis ("MS"), and spinal cord injury ("SCI") to rehabilitate and to stand and walk in neurorehabilitation settings and, for patients with a SCI, for home and community use, (ii) assist individuals with a broad range of upper extremity impairments, and (iii) allow industrial workers to perform difficult repetitive work for extended periods. Founded in 2005 , Liquidity and Going Concern As of June 30, 2024 six June 30, 2024 June 30, 2024 As described in Note 9. Notes Payable, net June 30, 2024 June 30, 2024 Our expectation to generate operating losses and negative operating cash flows in the future and the need for additional funding to support our planned operations raise substantial doubt regarding our ability to continue as a going concern for a period of one one no 12 The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 2. Basis of Presentation and Summary of Significant Accounting Policies and Estimates Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three six June 30, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation. Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss. Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at foreign financial institutions which throughout the year regularly exceed the applicable country cash deposit insurance limits of approximately $100 two $250 not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not June 30, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% June 30, 2024 (15% and 10%), as no December 31, 2023 During the three June 30, 2024 two 10% ue (11% and 10%), as three three June 30, 2023 During the six June 30, 2024 two 10% nue (12% and 10%), a two six June 30, 2023 Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. not 2023 07 Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06" 2020 06 may first 2024 not |
Note 3 - Accumulated Other Comp
Note 3 - Accumulated Other Comprehensive Income (Loss) | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Comprehensive Income (Loss) Note [Text Block] | 3. Accumulated Other Comprehensive Income (Loss) The Company's accumulated other comprehensive income (loss) consists of the accumulated net unrealized gains or losses on foreign currency translation adjustments. The change in accumulated other comprehensive income (loss) presented on the condensed consolidated balance sheets for the six June 30, 2024 2023 Six Months Ended June 30, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 383 (204 ) Balance at end of period $ 539 $ 359 |
Note 4 - Fair Value Measurement
Note 4 - Fair Value Measurement | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | 4. Fair Value Measurement Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two may • Level 1 • Level 2 1 not • Level 3 no 3 The Company’s fair value hierarchies for its financial assets and liabilities, which require fair value measurement on a recurring basis are as follows: Total Level 1 Level 2 Level 3 June 30, 2024 Liabilities Warrant liabilities $ 49 $ — $ — $ 49 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 six June 30, 2024 Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Gain on revaluation of warrants (426 ) Balance as of June 30, 2024 $ 49 Refer to Note 11. Capitalization and Equity Structure – Warrants . |
Note 5 - Inventories
Note 5 - Inventories | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Inventory Disclosure [Text Block] | 5. Inventories Inventories as of June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Raw materials $ 3,983 $ 4,298 Work in progress 217 290 Finished goods 774 462 Inventories $ 4,974 $ 5,050 |
Note 6 - Revenue
Note 6 - Revenue | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | 6. Revenue The Company’s medical device segment (EksoHealth) revenue is primarily generated through the sale and subscription of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices, along with the sale of support and maintenance contracts. Revenue from medical device product sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility for sales of the EksoNR, Ekso Indego Therapy, and Ekso Indego Personal devices. Support and maintenance contracts extend coverage beyond the Company’s standard warranty agreements ranging from 12 to 48 months. Revenue is recognized evenly over the term of the contracts. Revenue from medical device subscriptions is recognized evenly over the contract term, typically over 24 The Company’s industrial device segment (EksoWorks) revenue is primarily generated through the sale of the upper body exoskeleton EVO and associated accessories. Revenue from industrial device sales is recognized at the point in time when control of the product transfers to the customer. Transfer of control generally occurs upon shipment from the Company’s facility. Deferred Revenue Deferred revenue is comprised mainly of unearned revenue related to extended support and maintenance contracts, but also includes other offerings for which the Company has been paid in advance and earns revenue when the Company transfers control of the product or service. Deferred revenue consisted of the following: June 30, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,786 3,993 Deferred device and advances 156 169 Total deferred revenues 3,942 4,162 Less current portion (1,926 ) (1,993 ) Deferred revenues, non-current $ 2,016 $ 2,169 On September 25, 2023, Deferred revenue activity consisted of the following for the six June 30, 2024 Beginning balance $ 4,162 Deferral of revenue 1,166 Recognition of deferred revenue (1,386 ) Ending balance $ 3,942 The Company expects to recognize approximatel y $1,162 of the deferred revenue during the remainder of 2024 2025 In addition to deferred revenue, the Company has a non-cancellable backlog of $2,872, 2024 2026, not and Disaggregation of Revenue The following table disaggregates the Company’s revenue by major source for the three June 30, 2024 EksoHealth EksoWorks Total Device revenue $ 3,656 $ 159 $ 3,815 Service and support 836 — 836 Subscriptions 146 — 146 Parts and other 146 7 153 $ 4,784 $ 166 $ 4,950 The following table disaggregates the Company’s revenue by major source for the three June 30, 2023 EksoHealth EksoWorks Total Device revenue $ 3,603 $ 7 $ 3,610 Service and support 722 — 722 Subscriptions 261 4 265 Parts and other 102 4 106 $ 4,688 $ 15 $ 4,703 The following table disaggregates the Company’s revenue by major source for the six June 30, 2024 EksoHealth EksoWorks Total Device revenue $ 6,241 $ 327 $ 6,568 Service and support 1,601 — 1,601 Subscriptions 290 — 290 Parts and other 211 36 247 $ 8,343 $ 363 $ 8,706 The following table disaggregates the Company’s revenue by major source for the six June 30, 2023 EksoHealth EksoWorks Total Device revenue $ 6,651 $ 118 $ 6,769 Service and support 1,366 — 1,366 Subscriptions 536 11 547 Parts and other 131 12 143 $ 8,684 $ 141 $ 8,825 |
Note 7 - Accrued Liabilities
Note 7 - Accrued Liabilities | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] | 7. Accrued Liabilities Accrued liabilities as of June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,459 $ 2,058 Device warranty 417 461 Other 97 145 Total $ 1,973 $ 2,664 Warranty The current portion of the device warranty liability is classified as a component of Accrued liabilities, while the long-term portion of the device warranty liability is classified as a component of Other non-current liabilities in the condensed consolidated balance sheets. A reconciliation of the changes in the device warranty liability for the three six June 30, 2024 Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Balance at beginning of the period $ 526 $ 566 Additions for estimated future expense 195 316 Incurred costs (160 ) (321 ) Balance at end of the period $ 561 $ 561 Balance as of June 30, 2024 Current portion $ 417 Long-term portion 144 Total $ 561 |
Note 8 - Goodwill and Intangibl
Note 8 - Goodwill and Intangible Assets | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Goodwill and Intangible Assets Disclosure [Text Block] | 8. Goodwill and Intangible Assets On December 5, 2022, Goodwill The Company accounted for the acquisition as a business combination in accordance with ASC 805, The Compan y determined no three six June 30, 2024 2023. Intangible Assets The following table summarizes the components of gross assets, accumulated amortization, and net carrying values for definite and indefinite lived intangible asset balances as of June 30, 2024 December 31, 2023: June 30, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (453 ) $ 1,857 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (28 ) 112 Total intangible assets $ 5,220 $ (481 ) $ 4,739 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Total intangible assets $ 5,220 $ (328 ) $ 4,892 Definite lived intangible assets are amortized over their estimated lives using the straight line method, which is estimated as eight 12 eight one no ny determined no three six June 30, 2024 2023. The estimated future amortization expenses related to definite lived intangible assets as of June 30, 2024 Fiscal Year Amount 2024 - remainder $ 153 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 896 Total $ 2,429 Amortization expense related to the acquired definite lived intangible assets wa s $77 and $ three June 30, 2024 2023, six June 30, 2024 2023, |
Note 9 - Notes Payable, Net
Note 9 - Notes Payable, Net | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Long-Term Debt [Text Block] | 9. Notes Payable, net PWB Term Loan In August 2020, first The Company was required to pay accrued interest on the current loan on the 13th August 13, 2023, August 17, 2023, August 13, 2026 470, The PWB Loan Agreement contains a liquidity covenant, which requires that the Company maintain cash in accounts of the lender or subject to control agreements in favor of the lender in an amount equal to at least the outstanding balance of the PWB Term Loan, which was $2,000 as of June 30, 2024 June 30, 2024 The interest rate of the PWB Term Loan is subject to increase in the event of late payment and after occurrence of and during the continuation of an event of default. The Company may The debt issuance costs and debt discounts combined with the stated interest resulted in an effective interest ra te of 8.74% and 8.87% fo three June 30, 2024 2023, six June 30, 2024 2023, taled $44 for each of the three June 30, 2024 2023, $87 six June 30, 2024 2023. The following table presents scheduled principal payments of the Company’s PWB Term Loan as of June 30, 2024 Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (5 ) Note payable, net $ 1,995 Current portion $ — Long-term portion 1,995 Note payable, net $ 1,995 Parker Hannifin Promissory Note In connection with the HMC Acquisition, on December 5, 2022, sixteen December 31, 2023 September 30, 2027. The Promissory Note, upon the occurrence of an event of default, allows for the levying of interest equal to the lesser of (a) 5% per annum and (b) the maximum interest rate permitted under applicable law on the then entire outstanding principal balance, and also for the acceleration of all outstanding liabilities and obligations, making them immediately payable. Under the terms of the Promissory Note, the following occurrences constitute a default, and could, upon written notice or declaration by Parker, allow for the levying of interest and or the acceleration of principal outstanding: (i) failure to pay any amount of the principal when due and payable, (ii) the dissolution of the Company (including the declaration of bankruptcy), and (iii) the acquisition of the Company by another entity or the sale of substantially all of its assets to another entity. The Company recorded the Promissory Note of $4,055 in its condensed consolidated balance sheets under the captions Notes Payable, Current and Notes Payable, Net, estimating an implicit discount rate of 7.5% via reference to the interest charged on the Company's PWB Term Loan and other relevant economic factors present at the execution date of the Promissory Note. The amortization of debt discounts resulted in an effective interest r ate of 7.05% and 7.50% f three June 30, 2024 2023, six June 30, 2024 2023, as $70 and three June 30, 2024 2023, six June 30, 2024 2023, The following table presents scheduled principal payments of the Company's Promissory Note as of June 30, 2024 Period Amount 2024 - remainder $ 625 2025 1,250 2026 1,250 2027 938 Total principal payments 4,063 Less debt discount (456 ) Note payable, net $ 3,607 Current portion 1,250 Long-term portion 2,357 Note payable, net $ 3,607 |
Note 10 - Lease Obligations
Note 10 - Lease Obligations | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Lessee, Operating Leases [Text Block] | 10. Lease Obligations The Company's operating lease agreement for its headquarters and manufacturing facility in San Rafael, California (the "San Rafael Lease") commenced in July 2022 October 2026, three The San Rafael Lease constitutes an operating lease under ASC 842 July 2022 October 2026. three The Company's operating lease agreement for its office in Hamburg, Germany (the "Hamburg Lease") commenced in May 2022 June 2025 one five The Hamburg Lease constitutes a lease under ASC 842, May 2022 June 2025. five m the lease liability calculation and expensed as incurred. The Company records a straight-line monthly rent expense for this lease equal to the sum of all fixed lease payments divided by the number of months in the lease term. The Company entered into an operating lease agreement for its shared service and manufacturing facility in Brecksville, Ohio (the "Ohio Lease"), commencing in June 2024 July 2027, three July 2024, 14. Commitments and Contingencies – Material Contracts The Company has determined that the Ohio Lease constitutes an operating lease under ASC 842 July 2024 July 2027. three would make exercise reasonably certain. Fixed lease payments for identified lease components over the identified term were discounted at the Company's estimated incremental borrowing rate as of the date of contract execution and are reflected in th The Company’s future lease payments as of June 30, 2024 Periods Operating Leases 2024 - remainder $ 248 2025 483 2026 432 2027 41 Total lease payments 1,204 Less: imputed interest (115 ) Present value of lease liabilities $ 1,089 Weighted-average remaining lease term (in years) 2.38 Weighted-average discount rate 8.3 % Lease expense under the Company’s operating leases w as $135 and $1 38 three June 30, 2024 2023 six June 30, 2024 2023 |
Note 11 - Capitalization and Eq
Note 11 - Capitalization and Equity Structure | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Equity [Text Block] | 11. Capitalization and Equity Structure Summary The Company’s authorized capital stock at June 30, 2024 December 31, 2023 June 30, 2024 December 31, 2023 14,848 January 2024 On January 10, 2024, “January 2024 January 2024 January 2024 At the Market Offering In October 2020, may may June 2023, may not an $6.75 per share. During the three June 30, 2024, six June 30, 2024, not three six June 30, 2023. June 30, 2024, Warrants Warrants outstanding as of June 30, 2024 December 31, 2023 Source Exercise Price Remaining term (Years) December 31, 2023 Issued Expired Exercised June 30, 2024 2021 Warrants $ 12.81 1.6 273 — — — 273 June 2020 Investor Warrants $ 5.18 1.4 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.9 39 — — — 39 December 2019 Warrants $ 8.10 1.0 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.5 52 — — — 52 May 2019 Warrants $ 1.55 — 193 — (193 ) — — 1,240 — (193 ) — 1,047 No warrants were exercised during the three six June 30, 2024 2023 2021 In February 2021, "2021 2021 five February 11, 2026. In addition, the 2021 2021 2021 not may 2021 2021 2021 The 2021 2021 2021 30 2021 2021 five 2021 The warrant liability related to the 2021 3 2021 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.86 % 4.20 % Expected term (years) 1.61 2.11 Volatility of stock 97.1 % 76.5 % June 2020 In June 2020, "June 2020 June 2020 five one December 10, 2025. In addition, the June 2020 June 2020 June 2020 not may June 2020 June 2020 The June 2020 The June 2020 June 2020 June 2020 June 2020 June 2020 June 2020 30 June 2020 June 2020 June 2020 The warrant liability related to the June 2020 3 June 2020 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.92 % 4.26 % Expected term (years) 1.44 1.94 Volatility of stock 97.6 % 78.2 % June 2020 In June 2020, "June 2020 June 2020 June 2020 June 7, 2025. Because of the put-option provision in the June 2020 The warrant liability related to the June 2020 3 June 2020 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 5.12 % 4.54 % Expected term (years) 0.94 1.44 Volatility of stock 112.6 % 83.0 % December 2019 In December 2019, "December 2019 "December 2019 December 2019 five June 21, 2025. The December 2019 December 2019 December 2019 December 2019 December 2019 30 December 2019 December 2019 five December 2019 The warrant liability related to the December 2019 3 December 2019 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 5.11 % 4.53 % Expected term (years) 0.97 1.47 Volatility of stock 112.4 % 82.3 % December 2019 In December 2019, December 2019 "December 2019 December 2019 December 2019 December 18, 2025. The warrant liability related to the December 2019 3 December 2019 June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.35 % 4.82 % Expected term (years) 0.47 0.97 Volatility of stock 99.4 % 85.2 % Management has assessed that the likelihood of a Change of Control (as defined in the December 2019 December 2019 May 2019 In May 2019, "May 2019 "May 2019 The May 2019 five May 2024. The warrant liability related to the May 2019 3 May 2019 May 2019 June 30, 2024 December 31, 2023 Share price N/A $ 1.88 (1) Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.3 % Expected term (years) — 0.4 Volatility of stock N/A 77.5 % ( 1 December 31, 2023, first 2024, 25% |
Note 12 - Stock-based Compensat
Note 12 - Stock-based Compensation | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Share-Based Payment Arrangement [Text Block] | 12. Stock-based Compensation Shares available for grant The Company's Amended and Restated 2014 "2014 January 31, 2024. 2024 no 2014 June 6, 2024, 2014 2014 2014 April 15, 2034, 2014 June 30, 2024, 2014 were availabl Stock Options The following table summarizes information about the Company’s stock options outstanding as of June 30, 2024 six Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (60 ) 49.74 Balance as of June 30, 2024 192 $ 31.95 3.91 $ — Vested and expected to vest as of June 30, 2024 192 $ 31.95 3.91 $ — Exercisable as of June 30, 2024 192 $ 31.96 3.91 $ — There were no stock options awarded during the three six June 30, 2024 2023 June 30, 2024 Restricted Stock Units The Company issues time-based restricted stock units (“RSUs”) and performance-based restricted stock units ("PSUs") to employees and non-employees. Each RSU and PSU represents the right to receive one Combined RSU and PSU activity for the six June 30, 2024 Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 313 1.12 Vested (494 ) 1.80 Forfeited (42 ) 1.81 Unvested as of June 30, 2024 1,082 $ 1.44 As of June 30, 2024 $999 of total unrecognized compensation expense related to unvested RSUs and PSUs was expected to be recognized over a weighted average period of 1.14 ye Compensation Expense Stock-based compensation expense is included in the condensed consolidated statements of operations and comprehensive loss in general and administrative, research and development, or sales and marketing expenses, depending on the nature of the services provided. Stock-based compensation expense related to options, RSUs and PSUs was recorded as follows: Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales and marketing $ 6 $ 76 $ 58 $ 140 Research and development 81 131 171 213 General and administrative 198 307 431 585 $ 285 $ 514 $ 660 $ 938 401 During the six June 30, 2024 2023, d and 161 shares of common stock with a fair value of an 401 December 31, 2023 2022. The expense for the 401 six June 30, 2024 2023 |
Note 13 - Income Taxes
Note 13 - Income Taxes | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | 13. Income Taxes There were no six June 30, 2024 not |
Note 14 - Commitments and Conti
Note 14 - Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 14. Commitments and Contingencies Material Contracts The Company has two In connection with the HMC Acquisition, the Company assumed two The Vanderbilt Exoskeleton License Agreement was entered into as of October 15, 2012 April 29, 2038, The Vanderbilt Knee License Agreement was entered into as of March 1, 2022 February 15, 2041, July 31, 2028 Purchase Obligations The Company purchases components from a variety of suppliers and uses contract manufacturers to provide manufacturing services for its products. Purchase obligations are defined as agreements that are enforceable and legally binding and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum or variable price provisions; and the approximate timing of the transaction. The Company had purchase obligations primarily for purchases of inventory and manufacturing related service contracts totaling $2,137 as of June 30, 2024 one December 31, 2023 may The Company has operating lease commitments totaling $1,204 payable over 37 months related to the San Rafael Lease, the Ohio Lease, and the Hamburg Lease 10. Lease Obligations Loss Contingencies In the normal course of business, the Company is subject to various legal matters. In the opinion of management, the resolution of such matters will not |
Note 15 - Net Loss Per Share
Note 15 - Net Loss Per Share | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 15. Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (2,416 ) $ (4,230 ) $ (5,845 ) $ (8,619 ) Denominator: Weighted-average number of shares, basic and diluted 18,224 13,637 17,822 13,467 Net loss per common share, basic and diluted $ (0.13 ) $ (0.31 ) $ (0.33 ) $ (0.64 ) The following table sets forth potential shares of common stock that are not Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Options to purchase common stock 192 261 192 261 Restricted stock units 1,082 1,555 1,082 1,555 Warrants for common stock 1,047 1,240 1,047 1,240 Total common stock equivalents 2,321 3,056 2,321 3,056 |
Note 16 - Segment Disclosures
Note 16 - Segment Disclosures | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Segment Reporting Disclosure [Text Block] | 16. Segment Disclosures The Company has two The Company evaluates performance and allocates resources based on segment gross profit margin. The Company does not not Segment reporting information is as follows: EksoHealth EksoWorks Total Three months ended June 30, 2024 Revenue $ 4,784 $ 166 $ 4,950 Cost of revenue 2,196 117 2,313 Gross profit $ 2,588 $ 49 $ 2,637 Three months ended June 30, 2023 Revenue $ 4,688 $ 15 $ 4,703 Cost of revenue 2,421 28 2,449 Gross profit $ 2,267 $ (13 ) $ 2,254 EksoHealth EksoWorks Total Six months ended June 30, 2024 Revenue $ 8,343 $ 363 $ 8,706 Cost of revenue 3,852 266 4,118 Gross profit $ 4,491 $ 97 $ 4,588 Six months ended June 30, 2023 Revenue $ 8,684 $ 141 $ 8,825 Cost of revenue 4,372 199 4,571 Gross profit $ 4,312 $ (58 ) $ 4,254 The Company operates in the following regions: ( 1 2 3 10% three six June 30, 2024 2023 Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Americas United States $ 2,589 $ 3,684 $ 4,886 $ 6,642 Canada 330 6 352 8 Mexico — — 9 3 Other — — — — Americas revenue 2,919 3,691 5,247 6,653 EMEA France 522 — 868 1 Germany 418 52 543 296 Romania 181 475 181 475 Poland 57 284 96 511 Other 338 51 659 335 EMEA revenue 1,516 862 2,347 1,618 APAC Hong Kong 108 118 122 297 Indonesia 301 — 636 — Other 106 32 354 257 APAC revenue 515 150 1,112 554 Total Revenue $ 4,950 $ 4,703 $ 8,706 $ 8,825 |
Note 17 - Related Party Transac
Note 17 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2024 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | 17. Related Party Transactions On February 4, 2023, July 2017. one two The Company's total settlement amount was $325 and to be paid in cash over fourteen first twelve April 2024. f $0 June 30, 2024 December 31, 2023 |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended | 6 Months Ended |
Jun. 30, 2024 | Jun. 30, 2024 | |
Insider Trading Arr Line Items | ||
Material Terms of Trading Arrangement [Text Block] | During the quarter ended June 30, 2024, no 16a 1 10b5 1 10b5 1 408. | |
Rule 10b5-1 Arrangement Adopted [Flag] | false | |
Non-Rule 10b5-1 Arrangement Adopted [Flag] | false | |
Rule 10b5-1 Arrangement Terminated [Flag] | false | |
Non-Rule 10b5-1 Arrangement Terminated [Flag] | false |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2024 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation and Consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10 December 31, 2023 March 4, 2024. In the opinion of management, the accompanying unaudited condensed consolidated financial statements have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2023 The results of operations for the three six June 30, 2024 not December 31, 2024 The condensed consolidated financial statements include the financial statements of Ekso Bionics Holdings, Inc. and its subsidiaries. All significant transactions and balances between Ekso Bionics Holdings, Inc. and its subsidiaries have been eliminated in consolidation. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency The assets and liabilities of foreign subsidiaries and equity investments, where the local currency is the functional currency, are translated from their respective functional currencies into U.S. dollars at the rates in effect at the balance sheet date, and revenue and expense amounts are translated at average rates during the period, with resulting foreign currency translation adjustments recorded in accumulated other comprehensive income as a component of stockholders’ equity. Gains and losses from the re-measurement of balances denominated in currencies other than the entities' functional currencies, are recorded in other expense, net in the accompanying condensed consolidated statements of operations and comprehensive loss. |
Inventory, Policy [Policy Text Block] | Inventory Inventories are recorded at the lower of cost or net realizable value. Cost is computed using the standard cost method, which approximates actual cost on a first first |
Lessee, Leases [Policy Text Block] | Leases The Company records its leases in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") Topic 842, Leases not may Lease expense is recognized over the expected lease term on a straight-line basis. Operating leases are recognized on the balance sheet as right-of-use assets, lease liabilities current and lease liabilities non-current. Leases with an initial term of 12 not |
Revenue [Policy Text Block] | Revenue Recognition The Company records its revenue in accordance with ASC 606, Revenue from Contracts with Customers five For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are determined based on observable prices at which the Company separately sells its products or services. If a standalone selling price is not The Company exercised judgement to determine that a product return reserve was not not |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Concentration of Credit Risk and Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company has significant cash balances at foreign financial institutions which throughout the year regularly exceed the applicable country cash deposit insurance limits of approximately $100 two $250 not Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The allowance for potential credit losses on trade receivables reflects the Company’s best estimate of probable losses inherent in the accounts receivable balance based on known troubled accounts, historical experience, and other currently available evidence. Payment terms and conditions vary by contract type, although terms generally include a requirement of payment within 30 90 not June 30, 2024 December 31, 2023 Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not not The Company had two 10% June 30, 2024 (15% and 10%), as no December 31, 2023 During the three June 30, 2024 two 10% ue (11% and 10%), as three three June 30, 2023 During the six June 30, 2024 two 10% nue (12% and 10%), a two six June 30, 2023 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In November 2023, No. 2023 07, 280 2023 07" 2023 07 2023 07 December 15, 2023, December 15, 2024. not 2023 07 Accounting Pronouncements Adopted in 2024 In August 2020, No. 2020 06, 2020 06" 2020 06 may first 2024 not |
Note 3 - Accumulated Other Co_2
Note 3 - Accumulated Other Comprehensive Income (Loss) (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Six Months Ended June 30, 2024 2023 Balance at beginning of period $ 156 $ 563 Net unrealized gain (loss) on foreign currency translation 383 (204 ) Balance at end of period $ 539 $ 359 |
Note 4 - Fair Value Measureme_2
Note 4 - Fair Value Measurement (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | Total Level 1 Level 2 Level 3 June 30, 2024 Liabilities Warrant liabilities $ 49 $ — $ — $ 49 December 31, 2023 Liabilities Warrant liabilities $ 366 $ — $ — $ 366 |
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Warrant Liabilities Balance as of December 31, 2023 $ 366 Loss on modification of warrant 109 Gain on revaluation of warrants (426 ) Balance as of June 30, 2024 $ 49 |
Note 5 - Inventories (Tables)
Note 5 - Inventories (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | June 30, 2024 December 31, 2023 Raw materials $ 3,983 $ 4,298 Work in progress 217 290 Finished goods 774 462 Inventories $ 4,974 $ 5,050 |
Note 6 - Revenue (Tables)
Note 6 - Revenue (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] | June 30, 2024 December 31, 2023 Deferred extended maintenance and support $ 3,786 3,993 Deferred device and advances 156 169 Total deferred revenues 3,942 4,162 Less current portion (1,926 ) (1,993 ) Deferred revenues, non-current $ 2,016 $ 2,169 Beginning balance $ 4,162 Deferral of revenue 1,166 Recognition of deferred revenue (1,386 ) Ending balance $ 3,942 |
Disaggregation of Revenue [Table Text Block] | EksoHealth EksoWorks Total Device revenue $ 3,656 $ 159 $ 3,815 Service and support 836 — 836 Subscriptions 146 — 146 Parts and other 146 7 153 $ 4,784 $ 166 $ 4,950 EksoHealth EksoWorks Total Device revenue $ 3,603 $ 7 $ 3,610 Service and support 722 — 722 Subscriptions 261 4 265 Parts and other 102 4 106 $ 4,688 $ 15 $ 4,703 EksoHealth EksoWorks Total Device revenue $ 6,241 $ 327 $ 6,568 Service and support 1,601 — 1,601 Subscriptions 290 — 290 Parts and other 211 36 247 $ 8,343 $ 363 $ 8,706 EksoHealth EksoWorks Total Device revenue $ 6,651 $ 118 $ 6,769 Service and support 1,366 — 1,366 Subscriptions 536 11 547 Parts and other 131 12 143 $ 8,684 $ 141 $ 8,825 |
Note 7 - Accrued Liabilities (T
Note 7 - Accrued Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | June 30, 2024 December 31, 2023 Salaries, benefits and related expenses $ 1,459 $ 2,058 Device warranty 417 461 Other 97 145 Total $ 1,973 $ 2,664 |
Product Maintenance And Warranty [Table Text Block] | Three Months Ended Six Months Ended June 30, 2024 June 30, 2024 Balance at beginning of the period $ 526 $ 566 Additions for estimated future expense 195 316 Incurred costs (160 ) (321 ) Balance at end of the period $ 561 $ 561 Balance as of June 30, 2024 Current portion $ 417 Long-term portion 144 Total $ 561 |
Note 8 - Goodwill and Intangi_2
Note 8 - Goodwill and Intangible Assets (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Finite-Lived Intangible Assets [Table Text Block] | June 30, 2024 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (453 ) $ 1,857 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (28 ) 112 Total intangible assets $ 5,220 $ (481 ) $ 4,739 December 31, 2023 Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology $ 2,310 $ (310 ) $ 2,000 Trade name 2,310 N/A 2,310 Intellectual property 460 — 460 Customer relationships 140 (18 ) 122 Total intangible assets $ 5,220 $ (328 ) $ 4,892 |
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | Fiscal Year Amount 2024 - remainder $ 153 2025 345 2026 345 2027 345 2028 345 2029 and thereafter 896 Total $ 2,429 |
Note 9 - Notes Payable, Net (Ta
Note 9 - Notes Payable, Net (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Maturities of Long-Term Debt [Table Text Block] | Period Amount 2024-2025 $ — 2026 2,000 Total principal payments 2,000 Less debt discount and issuance cost (5 ) Note payable, net $ 1,995 Current portion $ — Long-term portion 1,995 Note payable, net $ 1,995 Period Amount 2024 - remainder $ 625 2025 1,250 2026 1,250 2027 938 Total principal payments 4,063 Less debt discount (456 ) Note payable, net $ 3,607 Current portion 1,250 Long-term portion 2,357 Note payable, net $ 3,607 |
Note 10 - Lease Obligations (Ta
Note 10 - Lease Obligations (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] | Periods Operating Leases 2024 - remainder $ 248 2025 483 2026 432 2027 41 Total lease payments 1,204 Less: imputed interest (115 ) Present value of lease liabilities $ 1,089 Weighted-average remaining lease term (in years) 2.38 Weighted-average discount rate 8.3 % |
Note 11 - Capitalization and _2
Note 11 - Capitalization and Equity Structure (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Source Exercise Price Remaining term (Years) December 31, 2023 Issued Expired Exercised June 30, 2024 2021 Warrants $ 12.81 1.6 273 — — — 273 June 2020 Investor Warrants $ 5.18 1.4 127 — — — 127 June 2020 Placement Agent Warrants $ 5.64 0.9 39 — — — 39 December 2019 Warrants $ 8.10 1.0 556 — — — 556 December 2019 Placement Agent Warrants $ 8.44 0.5 52 — — — 52 May 2019 Warrants $ 1.55 — 193 — (193 ) — — 1,240 — (193 ) — 1,047 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 12.81 $ 12.81 Risk-free interest rate 4.86 % 4.20 % Expected term (years) 1.61 2.11 Volatility of stock 97.1 % 76.5 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.18 $ 5.18 Risk-free interest rate 4.92 % 4.26 % Expected term (years) 1.44 1.94 Volatility of stock 97.6 % 78.2 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 5.64 $ 5.64 Risk-free interest rate 5.12 % 4.54 % Expected term (years) 0.94 1.44 Volatility of stock 112.6 % 83.0 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.10 $ 8.10 Risk-free interest rate 5.11 % 4.53 % Expected term (years) 0.97 1.47 Volatility of stock 112.4 % 82.3 % June 30, 2024 December 31, 2023 Current share price $ 1.06 $ 2.50 Conversion price $ 8.44 $ 8.44 Risk-free interest rate 5.35 % 4.82 % Expected term (years) 0.47 0.97 Volatility of stock 99.4 % 85.2 % June 30, 2024 December 31, 2023 Share price N/A $ 1.88 (1) Conversion price N/A $ 3.52 Risk-free interest rate N/A 5.3 % Expected term (years) — 0.4 Volatility of stock N/A 77.5 % |
Note 12 - Stock-based Compens_2
Note 12 - Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Share-Based Payment Arrangement, Option, Activity [Table Text Block] | Weighted- Average Weighted- Remaining Aggregate Stock Average Contractual Intrinsic Awards Exercise Price Life (Years) Value Balance as of December 31, 2023 252 $ 36.17 Options cancelled (60 ) 49.74 Balance as of June 30, 2024 192 $ 31.95 3.91 $ — Vested and expected to vest as of June 30, 2024 192 $ 31.95 3.91 $ — Exercisable as of June 30, 2024 192 $ 31.96 3.91 $ — |
Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block] | Weighted- Number of Average Grant Shares Date Fair Value Unvested as of December 31, 2023 1,305 $ 1.67 Granted 313 1.12 Vested (494 ) 1.80 Forfeited (42 ) 1.81 Unvested as of June 30, 2024 1,082 $ 1.44 |
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Sales and marketing $ 6 $ 76 $ 58 $ 140 Research and development 81 131 171 213 General and administrative 198 307 431 585 $ 285 $ 514 $ 660 $ 938 |
Note 15 - Net Loss Per Share (T
Note 15 - Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Numerator: Net loss applicable to common stockholders, basic and diluted $ (2,416 ) $ (4,230 ) $ (5,845 ) $ (8,619 ) Denominator: Weighted-average number of shares, basic and diluted 18,224 13,637 17,822 13,467 Net loss per common share, basic and diluted $ (0.13 ) $ (0.31 ) $ (0.33 ) $ (0.64 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Options to purchase common stock 192 261 192 261 Restricted stock units 1,082 1,555 1,082 1,555 Warrants for common stock 1,047 1,240 1,047 1,240 Total common stock equivalents 2,321 3,056 2,321 3,056 |
Note 16 - Segment Disclosures (
Note 16 - Segment Disclosures (Tables) | 6 Months Ended |
Jun. 30, 2024 | |
Notes Tables | |
Schedule of Segment Reporting Information, by Segment [Table Text Block] | EksoHealth EksoWorks Total Three months ended June 30, 2024 Revenue $ 4,784 $ 166 $ 4,950 Cost of revenue 2,196 117 2,313 Gross profit $ 2,588 $ 49 $ 2,637 Three months ended June 30, 2023 Revenue $ 4,688 $ 15 $ 4,703 Cost of revenue 2,421 28 2,449 Gross profit $ 2,267 $ (13 ) $ 2,254 EksoHealth EksoWorks Total Six months ended June 30, 2024 Revenue $ 8,343 $ 363 $ 8,706 Cost of revenue 3,852 266 4,118 Gross profit $ 4,491 $ 97 $ 4,588 Six months ended June 30, 2023 Revenue $ 8,684 $ 141 $ 8,825 Cost of revenue 4,372 199 4,571 Gross profit $ 4,312 $ (58 ) $ 4,254 |
Revenue from External Customers by Geographic Areas [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024 2023 Americas United States $ 2,589 $ 3,684 $ 4,886 $ 6,642 Canada 330 6 352 8 Mexico — — 9 3 Other — — — — Americas revenue 2,919 3,691 5,247 6,653 EMEA France 522 — 868 1 Germany 418 52 543 296 Romania 181 475 181 475 Poland 57 284 96 511 Other 338 51 659 335 EMEA revenue 1,516 862 2,347 1,618 APAC Hong Kong 108 118 122 297 Indonesia 301 — 636 — Other 106 32 354 257 APAC revenue 515 150 1,112 554 Total Revenue $ 4,950 $ 4,703 $ 8,706 $ 8,825 |
Note 1 - Organization (Details
Note 1 - Organization (Details Textual) - USD ($) $ in Thousands | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Retained Earnings (Accumulated Deficit) | $ (244,990) | $ (239,145) | |
Net Cash Provided by (Used in) Operating Activities | (6,136) | $ (7,117) | |
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents | 5,885 | ||
Debt Covenant, Covenant Compliance, Unrestricted Cash | 2,000 | ||
Unrestricted Cash | $ 3,885 |
Note 2 - Basis of Presentatio_2
Note 2 - Basis of Presentation and Summary of Significant Accounting Policies and Estimates (Details Textual) - Customer Concentration Risk [Member] | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Accounts Receivable [Member] | ||||
Number Of Customers | 2 | |||
Accounts Receivable [Member] | Customer A [Member] | ||||
Concentration Risk, Percentage | 15% | |||
Accounts Receivable [Member] | Customer B [Member] | ||||
Concentration Risk, Percentage | 10% | |||
Revenue from Contract with Customer Benchmark [Member] | ||||
Number Of Customers | 2 | 3 | 2 | 2 |
Revenue from Contract with Customer Benchmark [Member] | Customer A [Member] | ||||
Concentration Risk, Percentage | 11% | 18% | 12% | 16% |
Revenue from Contract with Customer Benchmark [Member] | Customer B [Member] | ||||
Concentration Risk, Percentage | 10% | 14% | 10% | 13% |
Revenue from Contract with Customer Benchmark [Member] | Customer C [Member] | ||||
Concentration Risk, Percentage | 10% |
Note 3 - Accumulated Other Co_3
Note 3 - Accumulated Other Comprehensive Income (Loss) - Disclosure of Changes in Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Jun. 30, 2023 | |
Balance | $ 12,606 | $ 25,442 |
Net unrealized gain (loss) on foreign currency translation | 383 | (204) |
Balance | 12,059 | 17,807 |
Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||
Balance | 156 | 563 |
Balance | $ 539 | $ 359 |
Note 4 - Fair Value Measureme_3
Note 4 - Fair Value Measurement - Fair Value Hierarchies (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Warrant liabilities | $ 49 | $ 366 |
Fair Value, Inputs, Level 1 [Member] | ||
Warrant liabilities | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | ||
Warrant liabilities | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Warrant liabilities | $ 49 | $ 366 |
Note 4 - Fair Value Measureme_4
Note 4 - Fair Value Measurement - Changes in Fair Value (Details) - Derivative Financial Instruments, Liabilities [Member] $ in Thousands | 6 Months Ended |
Jun. 30, 2024 USD ($) | |
Balance | $ 366 |
Loss on modification of warrant | 109 |
Gain on revaluation of warrants | (426) |
Balance | $ 49 |
Note 5 - Inventories - Inventor
Note 5 - Inventories - Inventories (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Raw materials | $ 3,983 | $ 4,298 |
Work in progress | 217 | 290 |
Finished goods | 774 | 462 |
Inventories | $ 4,974 | $ 5,050 |
Note 6 - Revenue 1 (Details Tex
Note 6 - Revenue 1 (Details Textual) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Sep. 25, 2023 | |
Contract With Customer, Liability, Non-Cancellable Backlog | $ 2,872 | |
Parker [Member] | ||
Deferred Revenue, Warranty Claim Lump Sum | $ 700 | |
Minimum [Member] | Ekso Health [Member] | ||
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month) | 12 months | |
Maximum [Member] | Ekso Health [Member] | ||
Contracts With Customer, Accounts Receivable, Payment Terms, Duration (Month) | 48 months |
Note 6 - Revenue 2 (Details Tex
Note 6 - Revenue 2 (Details Textual) $ in Thousands | Jun. 30, 2024 USD ($) |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,162 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,351 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | |
Revenue, Remaining Performance Obligation, Amount | $ 1,429 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period (Year) | 1 year |
Note 6 - Revenue - Deferred Rev
Note 6 - Revenue - Deferred Revenue (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Dec. 31, 2023 | |
Deferred extended maintenance and support | $ 3,786 | $ 3,993 |
Deferred device and advances | 156 | 169 |
Total deferred revenues | 3,942 | 4,162 |
Less current portion | (1,926) | (1,993) |
Deferred revenues, non-current | 2,016 | $ 2,169 |
Beginning balance | 4,162 | |
Deferral of revenue | 1,166 | |
Recognition of deferred revenue | (1,386) | |
Ending balance | $ 3,942 |
Note 6 - Revenue - Disaggregati
Note 6 - Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenue | $ 4,950 | $ 4,703 | $ 8,706 | $ 8,825 |
Ekso Health [Member] | ||||
Revenue | 4,784 | 4,688 | 8,343 | 8,684 |
Ekso Works [Member] | ||||
Revenue | 166 | 15 | 363 | 141 |
Product [Member] | ||||
Revenue | 3,815 | 3,610 | 6,568 | 6,769 |
Product [Member] | Ekso Health [Member] | ||||
Revenue | 3,656 | 3,603 | 6,241 | 6,651 |
Product [Member] | Ekso Works [Member] | ||||
Revenue | 159 | 7 | 327 | 118 |
Service [Member] | ||||
Revenue | 836 | 722 | 1,601 | 1,366 |
Service [Member] | Ekso Health [Member] | ||||
Revenue | 836 | 722 | 1,601 | 1,366 |
Service [Member] | Ekso Works [Member] | ||||
Revenue | 0 | 0 | 0 | 0 |
Subscription [Member] | ||||
Revenue | 146 | 265 | 290 | 547 |
Subscription [Member] | Ekso Health [Member] | ||||
Revenue | 146 | 261 | 290 | 536 |
Subscription [Member] | Ekso Works [Member] | ||||
Revenue | 0 | 4 | 0 | 11 |
Product and Service, Other [Member] | ||||
Revenue | 153 | 106 | 247 | 143 |
Product and Service, Other [Member] | Ekso Health [Member] | ||||
Revenue | 146 | 102 | 211 | 131 |
Product and Service, Other [Member] | Ekso Works [Member] | ||||
Revenue | $ 7 | $ 4 | $ 36 | $ 12 |
Note 7 - Accrued Liabilities -
Note 7 - Accrued Liabilities - Schedule of Accrued Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Salaries, benefits and related expenses | $ 1,459 | $ 2,058 |
Device warranty | 417 | 461 |
Other | 97 | 145 |
Total | $ 1,973 | $ 2,664 |
Note 7 - Accrued Liabilities _2
Note 7 - Accrued Liabilities - Warrant Liability (Details) - Warranty [Member] $ in Thousands | 3 Months Ended | 6 Months Ended |
Jun. 30, 2024 USD ($) | Jun. 30, 2024 USD ($) | |
Balance at beginning of the period | $ 526 | $ 566 |
Additions for estimated future expense | 195 | 316 |
Incurred costs | (160) | (321) |
Balance at end of the period | 561 | 561 |
Current portion | 417 | 417 |
Long-term portion | 144 | 144 |
Total | $ 561 | $ 561 |
Note 8 - Goodwill and Intangi_3
Note 8 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | |
Goodwill | $ 431 | $ 431 | $ 431 | ||
Below Market Lease, Amortization Period (Year) | 1 year | ||||
Acquired Finite-Lived Intangible Asset, Amortization | $ 77 | $ 82 | $ 153 | $ 163 | |
Developed Technology Rights [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 8 years | 8 years | |||
Intellectual Property [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 12 years | 12 years | |||
Customer Relationships [Member] | |||||
Finite-Lived Intangible Asset, Useful Life (Year) | 8 years | 8 years |
Note 8 - Goodwill and Intangi_4
Note 8 - Goodwill and Intangible Assets - Goodwill and Intangible Assets Balances (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Dec. 31, 2023 |
Intangibles, Net Carrying Amount | $ 2,429 | |
Total intangible assets | 5,220 | $ 5,220 |
Total intangible assets | (481) | (328) |
Total intangible assets | 4,739 | 4,892 |
Trade Names [Member] | ||
Intangibles, Gross Carrying Amount | 2,310 | 2,310 |
Developed Technology Rights [Member] | ||
Intangibles, Gross Carrying Amount | 2,310 | 2,310 |
Intangibles, Accumulated Amortization | (453) | (310) |
Intangibles, Net Carrying Amount | 1,857 | 2,000 |
Intellectual Property [Member] | ||
Intangibles, Gross Carrying Amount | 460 | 460 |
Intangibles, Accumulated Amortization | 0 | 0 |
Intangibles, Net Carrying Amount | 460 | 460 |
Customer Relationships [Member] | ||
Intangibles, Gross Carrying Amount | 140 | 140 |
Intangibles, Accumulated Amortization | (28) | (18) |
Intangibles, Net Carrying Amount | $ 112 | $ 122 |
Note 8 - Goodwill and Intangi_5
Note 8 - Goodwill and Intangible Assets - Schedule of Finite Lived Intangible Assets (Details) $ in Thousands | Jun. 30, 2024 USD ($) |
2024 - remainder | $ 153 |
2025 | 345 |
2026 | 345 |
2027 | 345 |
2028 | 345 |
2029 and thereafter | 896 |
Total | $ 2,429 |
Note 9 - Notes Payable, Net (De
Note 9 - Notes Payable, Net (Details Textual) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||
Dec. 05, 2022 USD ($) | Aug. 30, 2020 USD ($) | Jun. 30, 2024 USD ($) | Mar. 31, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | |
Term Loan [Member] | PWB Agreement [Member] | |||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 2,000 | ||||||
Debt Instrument, Basis Spread on Variable Rate | 0.50% | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.50% | ||||||
Long-Term Debt, Gross | $ 2,000 | $ 2,000 | $ 2,000 | ||||
Debt Instrument, Covenant Compliance, Maximum Deposits Outside Of United States | $ 1,000 | ||||||
Line of Credit Facility, Interest Rate During Period | 8.74% | 8.87% | 8.74% | 8.70% | |||
Interest Expense, Debt | $ 44 | $ 44 | $ 87 | ||||
Subordinated Debt [Member] | Promissory Note [Member] | |||||||
Debt Instrument, Basis Spread on Variable Rate | 5% | ||||||
Debt Instrument, Interest Rate, Stated Percentage | 0% | ||||||
Long-Term Debt, Gross | $ 4,063 | $ 4,063 | |||||
Line of Credit Facility, Interest Rate During Period | 7.05% | 7.50% | 7.30% | 7.50% | |||
Interest Expense, Debt | $ 70 | $ 79 | $ 145 | $ 159 | |||
Debt Instrument, Face Amount | $ 5,000 | ||||||
Debt Instrument, Periodic Payment, Number of Installments | 16 | ||||||
Subordinated Debt | $ 4,055 | $ 4,055 | |||||
Debt Instrument, Discount Rate, Percentage | 7.50% |
Note 9 - Notes Payable, Net - S
Note 9 - Notes Payable, Net - Schedule of Principle Payments (Details) - USD ($) $ in Thousands | Jun. 30, 2024 | Mar. 31, 2024 |
Term Loan [Member] | PWB Agreement [Member] | ||
2024-2025 | $ 0 | |
2026 | 2,000 | |
Long-Term Debt, Gross | 2,000 | $ 2,000 |
Less debt discount and issuance cost | (5) | |
Note payable, net | 1,995 | |
Current portion | 0 | |
Long-term portion | 1,995 | |
2026 | 2,000 | |
Total principal payments | 2,000 | $ 2,000 |
Note payable, net | 1,995 | |
Current portion | 0 | |
Long-term portion | 1,995 | |
Subordinated Debt [Member] | Promissory Note [Member] | ||
2026 | 1,250 | |
Long-Term Debt, Gross | 4,063 | |
Note payable, net | 3,607 | |
Current portion | 1,250 | |
Long-term portion | 2,357 | |
2024 - remainder | 625 | |
2025 | 1,250 | |
2026 | 1,250 | |
2027 | 938 | |
Total principal payments | 4,063 | |
Less debt discount | 456 | |
Note payable, net | 3,607 | |
Current portion | 1,250 | |
Long-term portion | $ 2,357 |
Note 10 - Lease Obligations (De
Note 10 - Lease Obligations (Details Textual) $ in Thousands | 3 Months Ended | 6 Months Ended | |||||
Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Mar. 31, 2024 | Jul. 31, 2022 | Feb. 28, 2022 | |
Operating Lease, Expense | $ 135 | $ 138 | $ 271 | $ 271 | |||
San Rafael California [Member] | |||||||
Lessee, Operating Lease, Renewal Term (Year) | 3 years | 3 years | |||||
Brecksville Ohio [Member] | |||||||
Lessee, Operating Lease, Renewal Term (Year) | 3 years | 3 years | |||||
Hamburg Germany [Member] | |||||||
Lessee, Operating Lease, Renewal Term (Year) | 5 years | ||||||
Lessee Operating Lease, Number of Extension | 1 |
Note 10 - Lease Obligations - S
Note 10 - Lease Obligations - Schedule of Future Lease Liabilities (Details) $ in Thousands | Jun. 30, 2024 USD ($) |
2024 - remainder | $ 248 |
2025 | 483 |
2026 | 432 |
2027 | 41 |
Lessee, Operating Lease, Liability, to be Paid | 1,204 |
Less: imputed interest | (115) |
Present value of lease liabilities | $ 1,089 |
Weighted-average remaining lease term (in years) (Year) | 2 years 4 months 17 days |
Weighted-average discount rate | 8.30% |
Note 11 - Capitalization and _3
Note 11 - Capitalization and Equity Structure (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||||||||||
Jan. 10, 2024 | Feb. 28, 2021 | Oct. 31, 2020 | Jun. 30, 2020 | Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | Dec. 31, 2023 | Dec. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | |
Common Stock, Shares Authorized (in shares) | 141,429 | 141,429 | 141,429 | ||||||||||
Preferred Stock, Shares Authorized (in shares) | 10,000 | 10,000 | 10,000 | ||||||||||
Common Stock, Shares, Outstanding (in shares) | 18,444 | 18,444 | 14,848 | ||||||||||
Preferred Stock, Shares Outstanding (in shares) | 0 | 0 | 0 | ||||||||||
Proceeds from Issuance of Common Stock | $ 4,017 | $ 0 | |||||||||||
Stock Issued During Period, Value, New Issues | $ 5,000 | $ 47 | $ 3,970 | ||||||||||
Class Of Warrant Or Warrants Exercised (in shares) | 0 | 0 | 0 | 0 | |||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 1,047 | 1,047 | 1,240 | ||||||||||
Common Stock, Shares, Issued (in shares) | 18,444 | 18,444 | 14,848 | ||||||||||
Preferred Stock, Shares Issued (in shares) | 0 | 0 | 0 | ||||||||||
A2021 Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 273 | 0 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 12.81 | $ 12.81 | $ 12.81 | ||||||||||
Class of Warrant or Right Expiration Period (Year) | 5 years | ||||||||||||
Class of Warrant or Right, Outstanding (in shares) | 273 | 273 | 273 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 7 months 6 days | 1 year 7 months 6 days | |||||||||||
June 2020 Investor Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.18 | $ 5.18 | $ 5.18 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 874 | 127 | 127 | 127 | |||||||||
Class of Warrant or Right Expiration Period (Year) | 5 years 6 months | ||||||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year 4 months 24 days | 1 year 4 months 24 days | |||||||||||
June 2020 Placement Agent Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 122 | 0 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 5.64 | $ 5.64 | $ 5.64 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 39 | 39 | 39 | ||||||||||
Warrants and Rights Outstanding, Term (Year) | 10 months 24 days | 10 months 24 days | |||||||||||
December 2019 Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.1 | $ 8.1 | $ 8.1 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 556 | 556 | 556 | 556 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 1 year | 1 year | 5 years | ||||||||||
December 2019 Placement Agent Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 8.44 | $ 8.44 | $ 8.44 | ||||||||||
Class of Warrant or Right, Outstanding (in shares) | 52 | 52 | 52 | 52 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 6 months | 6 months | |||||||||||
May 2019 Warrants [Member] | |||||||||||||
Class Of Warrant Or Right Issued (in shares) | 0 | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ 1.55 | $ 1.55 | |||||||||||
Class of Warrant or Right, Outstanding (in shares) | 0 | 0 | 193 | 444 | |||||||||
Warrants and Rights Outstanding, Term (Year) | 5 years | ||||||||||||
January 2024 Offering [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 2,968 | ||||||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 1.55 | ||||||||||||
Proceeds from Issuance of Common Stock | $ 3,932 | ||||||||||||
At the Market Offering [Member] | |||||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 75 | 0 | 105 | 0 | |||||||||
Proceeds from Issuance of Common Stock | $ 46 | $ 85 | |||||||||||
Shares Issued, Average Price Per Share (in dollars per share) | $ 1.42 | $ 1.43 | |||||||||||
Sale Of Stock, Stock Available For Issuance, Value | $ 4,134 | ||||||||||||
At the Market Offering [Member] | Minimum [Member] | |||||||||||||
Share Price (in dollars per share) | $ 6.75 |
Note 11 - Capitalization and _4
Note 11 - Capitalization and Equity Structure - Schedule of Warrant Share Activity (Details) - $ / shares shares in Thousands | 1 Months Ended | 6 Months Ended | ||||
Feb. 28, 2021 | Jun. 30, 2020 | Jun. 30, 2024 | Dec. 31, 2019 | Jun. 30, 2019 | May 31, 2019 | |
Balance (in shares) | 1,240 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants expired (in shares) | (193) | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 1,047 | |||||
A2021 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 12.81 | $ 12.81 | ||||
Term (Year) | 1 year 7 months 6 days | |||||
Balance (in shares) | 273 | |||||
Warrants issued (in shares) | 273 | 0 | ||||
Warrants expired (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 273 | |||||
June 2020 Investor Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 5.18 | $ 5.18 | ||||
Term (Year) | 1 year 4 months 24 days | |||||
Balance (in shares) | 127 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants expired (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 874 | 127 | ||||
June 2020 Placement Agent Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 5.64 | $ 5.64 | ||||
Term (Year) | 10 months 24 days | |||||
Balance (in shares) | 39 | |||||
Warrants issued (in shares) | 122 | 0 | ||||
Warrants expired (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 39 | |||||
December 2019 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 8.1 | $ 8.1 | ||||
Term (Year) | 1 year | 5 years | ||||
Balance (in shares) | 556 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants expired (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 556 | |||||
December 2019 Placement Agent Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 8.44 | $ 8.44 | ||||
Term (Year) | 6 months | |||||
Balance (in shares) | 52 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants expired (in shares) | 0 | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 52 | |||||
May 2019 Warrants [Member] | ||||||
Exercise price (in dollars per share) | $ 1.55 | |||||
Term (Year) | 5 years | |||||
Balance (in shares) | 193 | |||||
Warrants issued (in shares) | 0 | |||||
Warrants expired (in shares) | (193) | |||||
Warrants exercised (in shares) | 0 | |||||
Balance (in shares) | 0 |
Note 11 - Capitalization and _5
Note 11 - Capitalization and Equity Structure - Schedule of Assumptions used in Black-Scholes Model to Measure Fair Value (Details) | Jun. 30, 2024 | Dec. 31, 2023 | |
A2021 Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | 1.06 | 2.5 | |
A2021 Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 12.81 | 12.81 | |
A2021 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.0486 | 0.042 | |
A2021 Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 1.61 | 2.11 | |
A2021 Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 0.971 | 0.765 | |
June 2020 Investor Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | 1.06 | 2.5 | |
June 2020 Investor Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 5.18 | 5.18 | |
June 2020 Investor Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.0492 | 0.0426 | |
June 2020 Investor Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 1.44 | 1.94 | |
June 2020 Investor Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 0.976 | 0.782 | |
June 2020 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | 1.06 | 2.5 | |
June 2020 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 5.64 | 5.64 | |
June 2020 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.0512 | 0.0454 | |
June 2020 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 0.94 | 1.44 | |
June 2020 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 1.126 | 0.83 | |
December 2019 Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | 1.06 | 2.5 | |
December 2019 Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 8.1 | 8.1 | |
December 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.0511 | 0.0453 | |
December 2019 Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 0.97 | 1.47 | |
December 2019 Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 1.124 | 0.823 | |
December 2019 Placement Agent Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | 1.06 | 2.5 | |
December 2019 Placement Agent Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 8.44 | 8.44 | |
December 2019 Placement Agent Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.0535 | 0.0482 | |
December 2019 Placement Agent Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 0.47 | 0.97 | |
December 2019 Placement Agent Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 0.994 | 0.852 | |
May 2019 Warrants [Member] | Measurement Input, Share Price [Member] | |||
Warrant, measurement input | [1] | 1.88 | |
May 2019 Warrants [Member] | Measurement Input, Conversion Price [Member] | |||
Warrant, measurement input | 3.52 | ||
May 2019 Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member] | |||
Warrant, measurement input | 0.053 | ||
May 2019 Warrants [Member] | Measurement Input, Expected Term [Member] | |||
Warrant, measurement input | 0.4 | ||
May 2019 Warrants [Member] | Measurement Input, Price Volatility [Member] | |||
Warrant, measurement input | 0.775 | ||
[1]As of December 31, 2023, management determined that a financing event was likely in the first quarter of 2024, and reduced the share price used in the model by 25% in order to reflect the total amount that would be realized accordingly. |
Note 12 - Stock-based Compens_3
Note 12 - Stock-based Compensation (Details Textual) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 06, 2024 | Jun. 30, 2024 | Mar. 31, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 0 | 0 | 0 | 0 | ||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 0 | $ 0 | ||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 237 | $ 249 | ||||
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 50% | |||||
Common Stock Contribution | $ 113 | $ 219 | ||||
Additional Paid-in Capital [Member] | ||||||
Stock Issued During Period, Shares, Employee Benefit Plan (in shares) | 163 | 161 | ||||
Stock Issued During Period, Value, Employee Benefit Plan | $ 237 | $ 249 | $ 238 | $ 249 | ||
Restricted Stock Units (RSUs) [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares) | 313 | |||||
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | $ 999 | $ 999 | ||||
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year) | 1 year 1 month 20 days | |||||
Equity Incentive Plan 2014 [Member] | ||||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares) | 1,000 | |||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares) | 4,724 | 4,724 | ||||
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) | 1,066 | 1,066 |
Note 12 - Stock-based Compens_4
Note 12 - Stock-based Compensation - Stock Option Outstanding (Details) - Equity Incentive Plan 2014 [Member] $ / shares in Units, shares in Thousands, $ in Thousands | 6 Months Ended |
Jun. 30, 2024 USD ($) $ / shares shares | |
Balance (in shares) | shares | 252 |
Balance (in dollars per share) | $ / shares | $ 36.17 |
Options cancelled (in shares) | shares | (60) |
Options cancelled (in dollars per share) | $ / shares | $ 49.74 |
Balance (in shares) | shares | 192 |
Balance (in dollars per share) | $ / shares | $ 31.95 |
Balance as of June 30, 2024 (Year) | 3 years 10 months 28 days |
Balance as of June 30, 2024 | $ | $ 0 |
Vested and expected to vest as of June 30, 2024 (in shares) | shares | 192 |
Vested and expected to vest as of June 30, 2024 (in dollars per share) | $ / shares | $ 31.95 |
Vested and expected to vest as of June 30, 2024 (Year) | 3 years 10 months 28 days |
Vested and expected to vest as of June 30, 2024 | $ | $ 0 |
Exercisable as of June 30, 2024 (in shares) | shares | 192 |
Exercisable as of June 30, 2024 (in dollars per share) | $ / shares | $ 31.96 |
Exercisable as of June 30, 2024 (Year) | 3 years 10 months 28 days |
Exercisable as of June 30, 2024 | $ | $ 0 |
Note 12 - Stock-based Compens_5
Note 12 - Stock-based Compensation - RSU and PSU Activity (Details) - $ / shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Granted (in shares) | 0 | 0 | 0 | 0 |
Restricted Stock Units (RSUs) [Member] | ||||
Balance (in shares) | 1,305 | |||
Balance (in dollars per share) | $ 1.67 | |||
Granted (in shares) | 313 | |||
Granted (in dollars per share) | $ 1.12 | |||
Vested (in shares) | (494) | |||
Vested (in dollars per share) | $ 1.8 | |||
Forfeited (in shares) | (42) | |||
Forfeited (in dollars per share) | $ 1.81 | |||
Balance (in shares) | 1,082 | 1,082 | ||
Balance (in dollars per share) | $ 1.44 | $ 1.44 |
Note 12 - Stock-based Compens_6
Note 12 - Stock-based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Stock based compensation | $ 285 | $ 514 | $ 660 | $ 938 |
Selling and Marketing Expense [Member] | ||||
Stock based compensation | 6 | 76 | 58 | 140 |
Research and Development Expense [Member] | ||||
Stock based compensation | 81 | 131 | 171 | 213 |
General and Administrative Expense [Member] | ||||
Stock based compensation | $ 198 | $ 307 | $ 431 | $ 585 |
Note 14 - Commitments and Con_2
Note 14 - Commitments and Contingencies (Details Textual) $ in Thousands | 6 Months Ended | 18 Months Ended | |||
Mar. 01, 2022 USD ($) | Oct. 15, 2012 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2024 USD ($) | Dec. 31, 2023 USD ($) | |
Number Of License Agreements | 2 | 2 | |||
Purchase Obligation | $ 2,137 | $ 2,137 | $ 2,783 | ||
Long-Term Purchase Commitment, Period (Year) | 1 year | ||||
Lessee, Operating Lease, Liability, to be Paid | $ 1,204 | $ 1,204 | |||
San Rafael, Brecksville, and Hamburg [Member] | |||||
Lessee, Operating Lease, Term of Contract (Year) | 37 years | 37 years | |||
Royalty Agreement Terms [Member] | |||||
Royalty Percentage | 3.75% | ||||
Royalty Expense | $ 75 | $ 250 | $ 100 | ||
Royalty Agreement Terms [Member] | Licensed Patent Products [Member] | |||||
Royalty Percentage | 6% | ||||
Royalty Agreement Terms [Member] | Licensed Software Products [Member] | |||||
Royalty Percentage | 3% | ||||
Sales Revenue Goods Net Excluding Government Sales [Member] | Royalty Agreement Terms [Member] | |||||
Royalty Percentage | 1% | ||||
License Revenue [Member] | Royalty Agreement Terms [Member] | |||||
Royalty Percentage | 21% |
Note 15 - Net Loss Per Share -
Note 15 - Net Loss Per Share - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Net loss applicable to common stockholders, basic and diluted | $ (2,416) | $ (4,230) | $ (5,845) | $ (8,619) |
Weighted-average number of shares, basic and diluted (in shares) | 18,224 | 13,637 | 17,822 | 13,467 |
Net loss per common share, basic and diluted (in dollars per share) | $ (0.13) | $ (0.31) | $ (0.33) | $ (0.64) |
Note 15 - Net Loss Per Share _2
Note 15 - Net Loss Per Share - Schedule of Antidilutive Securities (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Antidilutive Securities (in shares) | 2,321 | 3,056 | 2,321 | 3,056 |
Share-Based Payment Arrangement, Option [Member] | ||||
Antidilutive Securities (in shares) | 192 | 261 | 192 | 261 |
Restricted Stock [Member] | ||||
Antidilutive Securities (in shares) | 1,082 | 1,555 | 1,082 | 1,555 |
Warrant [Member] | ||||
Antidilutive Securities (in shares) | 1,047 | 1,240 | 1,047 | 1,240 |
Note 16 - Segment Disclosures_2
Note 16 - Segment Disclosures (Details Textual) | 6 Months Ended |
Jun. 30, 2024 | |
Number of Reportable Segments | 2 |
Note 16 - Segment Disclosures -
Note 16 - Segment Disclosures - Segment Reporting Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenue | $ 4,950 | $ 4,703 | $ 8,706 | $ 8,825 |
Cost of revenue | 2,313 | 2,449 | 4,118 | 4,571 |
Gross profit | 2,637 | 2,254 | 4,588 | 4,254 |
Ekso Health [Member] | ||||
Revenue | 4,784 | 4,688 | 8,343 | 8,684 |
Cost of revenue | 2,196 | 2,421 | 3,852 | 4,372 |
Gross profit | 2,588 | 2,267 | 4,491 | 4,312 |
Ekso Works [Member] | ||||
Revenue | 166 | 15 | 363 | 141 |
Cost of revenue | 117 | 28 | 266 | 199 |
Gross profit | $ 49 | $ (13) | $ 97 | $ (58) |
Note 16 - Segment Disclosures_3
Note 16 - Segment Disclosures - Geographic Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2024 | Jun. 30, 2023 | Jun. 30, 2024 | Jun. 30, 2023 | |
Revenue | $ 4,950 | $ 4,703 | $ 8,706 | $ 8,825 |
UNITED STATES | ||||
Revenue | 2,589 | 3,684 | 4,886 | 6,642 |
CANADA | ||||
Revenue | 330 | 6 | 352 | 8 |
MEXICO | ||||
Revenue | 0 | 0 | 9 | 3 |
Americas Other [Member] | ||||
Revenue | 0 | 0 | 0 | 0 |
Americas [Member] | ||||
Revenue | 2,919 | 3,691 | 5,247 | 6,653 |
FRANCE | ||||
Revenue | 522 | 0 | 868 | 1 |
GERMANY | ||||
Revenue | 418 | 52 | 543 | 296 |
ROMANIA | ||||
Revenue | 181 | 475 | 181 | 475 |
POLAND | ||||
Revenue | 57 | 284 | 96 | 511 |
EMEA Other [Member] | ||||
Revenue | 338 | 51 | 659 | 335 |
EMEA [Member] | ||||
Revenue | 1,516 | 862 | 2,347 | 1,618 |
HONG KONG | ||||
Revenue | 108 | 118 | 122 | 297 |
INDONESIA | ||||
Revenue | 301 | 0 | 636 | 0 |
APAC Other [Member] | ||||
Revenue | 106 | 32 | 354 | 257 |
Asia Pacific [Member] | ||||
Revenue | $ 515 | $ 150 | $ 1,112 | $ 554 |
Note 17 - Related Party Trans_2
Note 17 - Related Party Transactions (Details Textual) - Angel Pond Capital LLC [Member] - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2024 | Dec. 31, 2023 | |
Related Party Transaction, Amounts of Transaction | $ 325 | |
Related Party Transaction, Payment Term (Year) | 14 years | |
Accounts Payable | $ 0 | $ 60 |
Initial Payment1 [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 145 | |
Related Party Transaction, Payment Term (Year) | 40 months | |
Initial Payment [Member] | ||
Related Party Transaction, Amounts of Transaction | $ 15 | |
Initial Payment2 [Member] | ||
Related Party Transaction, Payment Term (Year) | 12 years |